|
You are here : Home > News
Senexis
in the news
- independent articles
Articles
published in the trade press:
- Channel M Today (03/02/10), Dementia Report:
Prof. Andrew Doig interviewed
- Business Weekly (21/01/10), Page IX:
Senexis has
qualities to become a "great"
- Business Weekly (26/11/09), Page IV:
Senexis has
ingredients to become global star
- Business Weekly (19/11/09), Page 4:
Senexis file two
further patents
- Cambridge Evening News (03/11/09), Page
19: Region's top performers put on a
winning show
- Business Weekly (22/10/09), Page XV:
Entrepreneurship
encouraged at Babraham
- Cambridge Business (Q4 2009), Issue 4, Page 10:
Confused about
Alzheimer's?
- Business Weekly (15/10/09), Page 10:
Q10: talking heads
- Business Weekly (08/10/09), Page 20:
2009 awards
boost morale
- Business Weekly (30/09/09), Page 11:
Epigenetics to
revolutionise healthcare
- Business Weekly (17/09/09), Page 16:
Great year as
Senexis racks up the plaudits
- Business Weekly (10/09/09), Page 17:
Awards 2009:
Disruption, disruption, disruption
- BioWorld International (09/09/09) Senexis passes Wellcome
Trust milestone
- BioWorld (04/09/09) Senexis secures funding from the
Wellcome Trust to select candidate
- Cambridge Evening News (01/09/09) Business Section (page
17): Senexis grant boost
- BioWorld (27/08/09) Senexis awarded grant from EEDA for
Alzheimer's drug
- Business Weekly (27/08/09), Page 13:
Senexis awarded grant
for Alzheimer's work
- Cambridge Evening News (07/07/09) Business Section (page 17): Senexis
tackles disease
- Business Weekly (02/07/09), Page 8:
Senexis wins funding to fight
muscle disease
- Journal of UKSPA (May 2009), Page 41:
Five years on the road to drug
discovery
- UK Trade & Investment today (15/12/08) UK pharma firm
collaborates on Alzheimer's test
- Australian Life Scientist (11/12/08)
Alzhyme signs an agreement with Senexis
- Business Weekly (10/12/08)
Senexis in Oz Alzheimer's
diagnostics tie-up
- Business Weekly (27/11/08), Page 16:
Senexis to expand into diagnostics
- Business Weekly (17/07/08), Page VII:
Senexis' main focus on Alzheimer's
disease
- Business Wire 2008 (12/06/08) The CNS Market 2008 Report
- Bio-Medicine (14/02/08) Senexis and O2H announce
medicinal chemistry collaboration
- BIOTAQ (14/02/08) Senexis and O2H announce medicinal
chemistry collaboration
- CNS Drug News (01/02/08) Senexis raises funds to further
develop AD compounds
- Business Weekly (31/01/08), Page V:
Senexis: unfolding the
science of senescence
- Business Weekly (23/01/08) Senexis lands £2.9m Wellcome
funding for Alzheimer's
- BioWorld International (22/01/08) Senexis awarded $5.7m from the
Wellcome Trust
- BioCentury (21/01/08) Senexis receives $5.7 million from the
Wellcome Trust
- Science Business (18/01/08) UK drug developer gets £3.7
million for Alzheimer's
- Dow Jones Venture Wire (18/01/08) Senexis swallows $7.3 million
series A
- Silicon Fen Business Report (18/01/08) Senexis raises
£2.9 million
- Chemical Business (17/01/08) Senexis secures £0.8 million
from BTG
- Current Patents Gazette (13/04/07) Senexis files small
molecule patent
- Business Week (16/01/07) Senexis and Daniolabs to
collaborate
- News RX (11/04/06) Alzheimer's compounds licensed to
Senexis
- Silicon Fen Business Report (04/02/06) BTG and the
Wellcome Trust invest in Senexis
- Biospace (12/2/2005)
Senexis and BioFocus collaborate to select development candidates
for Senexis' Alzheimer's disease targets
- Chemistry & Industry (17/01/05) Movers and Shakers
- BioCentury (18/04/2005)
Emerging Company Profile - Senexis: Break it up
- Genetic Engineering News (01/09/2004)
Biotechnology Firms Settle in Cambridge, UK
- In Vivo Europe (01/07/2004)
RX Starting Out: Senexis
- Current Opinion in Structural Biology (2003)
Design strategies for anti-amyloid agents
- Biotechnology Investment Today (Summer 2003)
Meptides: a potential treatment for neurodegenerative diseases
- Genetic Engineering News (01/02/2003)
New UK Company targets Amyloidosis
|
|
|